The global pharmaceutical market is poised to surpass $3 trillion by 2034, driven by an aging population, increasing chronic diseases, and breakthroughs in innovative therapies like gene therapy and artificial intelligence-driven drug development. While the United States and Europe currently lead the industry, China is rapidly expanding its capabilities and reshaping the competitive landscape, according to a new industry report from the Korea Pharmaceutical and Bio-Association (KPBMA). The market size grew from $1 trillion in 2015 to $1.67 trillion in 2024, and is projected to reach $3 trillion by 2034 with an annual growth rate of 6.2% .
This shift comes as the US, Europe, and China increasingly view the pharmaceutical and biotechnology sectors as strategically vital, deploying a combination of tariffs, pricing regulations, supply chain controls, and digital transformation initiatives to establish a new global order. The KPBMA report, titled ‘2026 Pharmaceutical and Bio Industry Outlook (Focusing on the US, Europe, and China)’, analyzes these trends and their implications for the Korean pharmaceutical industry.
The administration of former US President Donald Trump is expected to prioritize trade leverage through tariffs, particularly Section 232 tariffs, if re-elected. This policy direction signals a focus on “security + price + finance” within the US pharmaceutical sector, with US pharmaceutical spending reaching $487.1 billion in 2024, a 7% average annual increase over the past five years.
Meanwhile, China is actively courting European nations, offering economic incentives and strengthening diplomatic ties. In February 2026, China secured a deal to purchase 120 Airbus aircraft from Germany, a move that followed a similar pattern of offering economic benefits to countries like the UK, Canada, and France in exchange for increased cooperation . This strategy appears to be a response to what China perceives as a unilateral and unpredictable approach from the US under Trump, as reported by IMBC News.
Europe, facing a fractured alliance with the US, is increasingly looking to China as a more predictable partner. The shift is highlighted by Germany’s recent strengthening of ties with China, and a growing sentiment that the US is no longer a reliable ally. China has also called on Europe to bolster its strategic autonomy, criticizing the US for allegedly undermining Europe’s potential to act as an independent global actor .
The evolving dynamics are prompting a reassessment of risks within the Korean pharmaceutical and biotechnology industry. The KPBMA emphasizes the need for domestic companies to address structural vulnerabilities and prepare for the changing global landscape.
The competition isn’t limited to economic factors. The rise of AI and digital transformation is also playing a crucial role, with all three major players – the US, Europe, and China – investing heavily in these areas to accelerate drug development and enhance their competitive edge.
As the global pharmaceutical market continues to grow and evolve, the interplay between the US, Europe, and China will be critical in shaping its future. The KPBMA report suggests that navigating this complex geopolitical landscape will be a key challenge for the Korean pharmaceutical industry in the years to reach.
What remains to be seen is how these shifting alliances and trade policies will impact access to medicines and the pace of innovation globally. The ongoing competition between these major players will likely continue to drive investment in research and development, but also raises questions about potential disruptions to supply chains and increased regulatory hurdles.
Share your thoughts on these developments in the comments below, and be sure to share this article with your network.
